Publication:
Synthesis and Biological Evaluation of Novel Bromophenol Derivatives as Carbonic Anhydrase Inhibitors

dc.authorscopusid36099972100
dc.authorscopusid6505649833
dc.authorscopusid6603339039
dc.authorscopusid6701789599
dc.authorscopusid55550270900
dc.authorscopusid23027537500
dc.contributor.authorAkbaba, Y.
dc.contributor.authorBalaydin, H.T.
dc.contributor.authorMenzek, A.
dc.contributor.authorGöksu, S.
dc.contributor.authorŞahin, E.
dc.contributor.authorEkinci, D.
dc.date.accessioned2020-06-21T14:05:24Z
dc.date.available2020-06-21T14:05:24Z
dc.date.issued2013
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Akbaba] Yusuf, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey; [Balaydin] Halis Türker, Department of Mathematics and Science Education, Artvin Coruh University, Artvin, Artvin, Turkey; [Menzek] Abdullah Elah, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey; [Göksu] Süleyman, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey; [Şahin] Ertan, Department of Chemistry, Atatürk Üniversitesi, Erzurum, Erzurum, Turkey; [Ekinci] Deniz, Department of Agricultural Biotechnology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractHere, we provide an alternative synthesis of the natural bromophenol 3,4-dibromo-5-(2,3-dibromo-4,5- dihydroxybenzyl)-6-(ethoxymethyl)benzene-1,2- diol (3) and the first synthesis of (4,5-dihydroxy-2- methylphenyl)(3,4- dihydroxyphenyl)methanone (18) and its brominated derivatives 19-21. The compounds were characterized and tested against the two most studied members of the pH regulatory enzyme family, carbonic anhydrase (CA). The inhibitory potencies of the novel compounds and two natural bromophenols 2, 3 were analyzed at the human isoforms hCA I and hCA II as targets and the K<inf>I</inf> values were calculated. The K<inf>I</inf> values of the novel compounds were measured in the range of 13.7-32.7 μM for the hCA I isozyme and 0.65-1.26 μM for the hCA II isozyme. The structurally related compound 14 was also tested in order to understand the structure-activity relationship, and the clinically used sulfonamide acetazolamide (AZA)was tested for comparison reasons. All of the compounds exhibited competitive inhibition with 4-nitrophenylacetate as substrate. The compounds showed strong inhibitory activity against hCA I, being more effective as compared to the clinically used AZA (K<inf>I</inf>: 36.2 μM), but rather less activity against hCA II. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA., Weinheim.en_US
dc.identifier.doi10.1002/ardp.201300054
dc.identifier.endpage454en_US
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue6en_US
dc.identifier.pmid23649517
dc.identifier.scopus2-s2.0-84879284688
dc.identifier.scopusqualityQ1
dc.identifier.startpage447en_US
dc.identifier.urihttps://doi.org/10.1002/ardp.201300054
dc.identifier.volume346en_US
dc.identifier.wosWOS:000320473000003
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherWiley-VCH Verlag GmbHen_US
dc.relation.ispartofArchiv Der Pharmazieen_US
dc.relation.journalArchiv Der Pharmazieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBrominationen_US
dc.subjectBromophenolsen_US
dc.subjectCarbonic Anhydrase Inhibitorsen_US
dc.subjectNatural Productsen_US
dc.titleSynthesis and Biological Evaluation of Novel Bromophenol Derivatives as Carbonic Anhydrase Inhibitorsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files